Operator: Good morning. Thank you for standing by. Welcome to the AbbVie Fourth Quarter 2022 Earnings Conference Call. I would now like to turn introduce the call to Ms.
- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive.
/PRNewswire/ AbbVie (NYSE: ABBV) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI.